Skip to main content

Table 3 Immunogenicity—total antibody developing incidence in OLE study

From: An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis

  Antibody-positive post-baseline of the OLE study with a negative or no result at baseline of the OLE study Antibody positive in the OLE study with a negative or no result at baseline of the parent study
ABP 501/ABP 501 (N = 229) RP/ABP 501 (N = 237) ABP 501/ABP 501 (N = 229) RP/ABP 501 (N = 237)
Binding antibody, n (%) 50 (21.8) 35 (14.8) 122 (53.3) 112 (47.3)
Neutralizing antibody, n (%) 20 (8.7) 12 (5.1) 33 (14.4) 33 (13.9)
  1. ABP 501/ABP 501 patients who continued on ABP 501 from the parent study, RP/ABP 501 patients who transitioned from RP in the parent study to ABP 501 in the OLE study